Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 1-year outcomes, with a mean gradient of 7.3 mm Hg and greater than mild paravalvular leakage in 3.6% of patients.
Observational (n=1,000)
Yes
Does transfemoral implantation of the ACURATE neo transcatheter heart valve result in favorable 1-year clinical and echocardiographic outcomes in a real-world patient population?
Transfemoral implantation of the ACURATE neo transcatheter heart valve demonstrates favorable 1-year hemodynamics and low rates of paravalvular leak, mortality, and new pacemakers in a real-world European registry.
OBJECTIVES: The SAVI-TF (Symetis ACURATE neo Valve Implantation Using Transfemoral Access) registry was initiated to study the ACURATE neo transcatheter heart valve in a large patient population treated under real-world conditions. BACKGROUND: The self-expanding, supra-annular ACURATE neo prosthesis is a transcatheter heart valve that gained the Conformité Européene mark in 2014, but only limited clinical data are available so far. METHODS: This prospective, multicenter registry enrolled 1,000 patients at 25 European centers who were followed for 1 year post-procedure. RESULTS: , mean gradient was 7.3 ± 3.7 mm Hg, and greater than mild paravalvular leakage was observed in 3.6% of patients. CONCLUSIONS: Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 1-year clinical and echocardiographic outcomes with very low mortality and new pacemaker rates.
Kim et al. (Sun,) conducted a observational in Transcatheter heart valve implantation (n=1,000). ACURATE neo transcatheter heart valve was evaluated on Mean gradient and paravalvular leakage. Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 1-year outcomes, with a mean gradient of 7.3 mm Hg and greater than mild paravalvular leakage in 3.6% of patients.